GlassScriptPhysician profile
David H Rosenstein
NPI 1518001551
$8,211.68
in general payments reported to CMS, 2019-2025
52 companies · $975 in 2025
The $975 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $631 · 2021: $2,263 · 2022: $1,436 · 2023: $1,095 · 2024: $1,165 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,235.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,277.21 | 2020-2021 | |
| Novo Nordisk INC | $1,024.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $756.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $735.69 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $685.24 | 2019-2025 | |
| Abbvie INC. | $502.70 | 2020-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $396.62 | 2020-2024 | Repatha, Otezla |
| Lilly USA, LLC | $274.99 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $221.75 | 2019-2024 | Farxiga |
| Amarin Pharma, INC. | $192.28 | 2019-2021 | |
| Abbott Laboratories | $184.13 | 2021-2023 | Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $173.80 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.11 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $149.98 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $132.71 | 2021-2025 | Rexulti |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rosenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.